<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713126</url>
  </required_header>
  <id_info>
    <org_study_id>16-001467</org_study_id>
    <secondary_id>R01HL128526</secondary_id>
    <nct_id>NCT02713126</nct_id>
  </id_info>
  <brief_title>Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in Heart Failure With Preserved Ejection Fraction (HFpEF) (INABLE-Training)</brief_title>
  <acronym>INABLE</acronym>
  <official_title>Inorganic Nitrite to Enhance Benefits From Exercise Training in Heart Failure With Preserved Ejection Fraction (HFpEF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barry Borlaug</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants with heart failure with preserved ejection fraction will undergo 12 weeks of&#xD;
      cardiac rehabilitation for exercise training (ET) and be randomized to either oral sodium&#xD;
      nitrite capsules or oral placebo capsules through the training period. Study drug is&#xD;
      administered 3 times daily during daytime hours with one of these doses being 30 minutes&#xD;
      prior to onset of ET sessions throughout the12 week trial. The objective is to determine if&#xD;
      the oral sodium nitrite improves the clinical responses and tolerability of ET.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in exercise capacity</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in exercise capacity as measured by peak oxygen consumption</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in daily activity levels</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in daily activity as assessed by accelerometer data; device worn continuously</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamics</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in hemodynamics and ventricular function measured during echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life score</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in Quality of Life score, as measured using the Kansas City Cardiomyopathy Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms of heart failure</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will undergo cardiac exercise training and receive oral placebo capsules three times per day for 12 weeks while wearing an accelerometer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Nitrite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo cardiac exercise training and receive oral sodium nitrite capsules three times per day for 12 weeks while wearing an accelerometer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Solution</intervention_name>
    <description>Placebo capsule administered orally, taken every 4 hours or 3 times per day during waking hours for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Sodium Nitrite</intervention_name>
    <description>Oral Sodium Nitrite, 40 mg administered orally, taken every 4 hours or 3 times per day during waking hours for 12 weeks</description>
    <arm_group_label>Sodium Nitrite</arm_group_label>
    <other_name>Nitrite</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Accelerometer</intervention_name>
    <description>External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sodium Nitrite</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac Exercise Training</intervention_name>
    <description>Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sodium Nitrite</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 40 years&#xD;
&#xD;
          -  Symptoms of dyspnea (II-IV) without evidence of a non-cardiac or ischemic explanation&#xD;
             for dyspnea&#xD;
&#xD;
          -  Ejection Fraction (EF) of &gt; or = 50% determined on most recent imaging study within&#xD;
             the preceding 5 years, with no change in clinical status suggesting potential for&#xD;
             deterioration in systolic function&#xD;
&#xD;
          -  One of the following:&#xD;
&#xD;
               -  Previous hospitalization for Heart Failure (HF) with radiographic evidence&#xD;
                  (pulmonary venous hypertension, vascular congestion, interstitial edema, pleural&#xD;
                  effusion) of pulmonary congestion or&#xD;
&#xD;
               -  Catheterization documented elevated filling pressures at rest (Pulmonary&#xD;
                  Capillary Wedge Pressure (PCWP)= ≥15 or Left Ventricular End-Diastolic Pressure&#xD;
                  (LVEDP) ≥18) or with exercise (PCWP ≥25) or&#xD;
&#xD;
               -  Elevated Natruretic Peptide-proBNP (&gt;400 pg/ml) or B-Type Natriuretic Peptide&#xD;
                  (BNP)(&gt;200 pg/ml) or&#xD;
&#xD;
               -  Echo evidence of diastolic dysfunction/elevated filling pressures manifest by&#xD;
                  medial E/e' ratio≥15 and/or left atrial enlargement and chronic treatment with a&#xD;
                  diuretic for signs or symptoms of heart failure&#xD;
&#xD;
          -  Heart failure is primary factor limiting activity as indicated by answering # 2 to the&#xD;
             following question:&#xD;
&#xD;
        My ability to be active is most limited by:&#xD;
&#xD;
          1. Joint, foot, leg, hip or back pain&#xD;
&#xD;
          2. Shortness of breath and/or fatigue and/or chest pain&#xD;
&#xD;
          3. Unsteadiness or dizziness&#xD;
&#xD;
          4. Lifestyle, weather, or I just don't like to be active&#xD;
&#xD;
               -  No chronic nitrate therapy or not using intermittent sublingual nitroglycerin&#xD;
                  (requirement for &gt;1 sublingual nitroglycerin per week).&#xD;
&#xD;
               -  No daily use of phosphodiesterase 5 (PDE5) inhibitors or soluble guanylyl cyclase&#xD;
                  activators and willing to withhold as needed use of PDE5 inhibitors for duration&#xD;
                  of study&#xD;
&#xD;
               -  Ambulatory (not wheelchair / scooter dependent)&#xD;
&#xD;
               -  Body size allows wearing of the accelerometer belt as confirmed by ability to&#xD;
                  comfortably fasten the test belt provided for the screening process.&#xD;
&#xD;
               -  Willingness to wear the accelerometer belt for the duration of the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent (&lt; 1 month) hospitalization for heart failure&#xD;
&#xD;
          -  Ongoing requirement for PDE5 inhibitor, organic nitrate or soluble guanylyl cyclase&#xD;
             activators&#xD;
&#xD;
          -  Hemoglobin (Hgb) &lt; 8.0 g/dl within 30 days prior to randomization&#xD;
&#xD;
          -  Glomerular Filtration Rate (GFR) &lt; 20 ml/min/1.73 m2 within 30 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Systolic blood pressure &lt; 115 mmHg seated or &lt; 90 mmHg standing&#xD;
&#xD;
          -  Resting Heart Rate &gt; 110&#xD;
&#xD;
          -  Previous adverse reaction to the study drug which necessitated withdrawal of therapy&#xD;
&#xD;
          -  Significant chronic obstructive pulmonary disease that is a primary contributor to&#xD;
             symptoms, in the opinion of the Investigator.&#xD;
&#xD;
          -  Ischemia thought to contribute to dyspnea, in the opinion of the Investigator.&#xD;
&#xD;
          -  Documentation of previous Ejection Fraction &lt; 40%&#xD;
&#xD;
          -  Acute coronary syndrome within 3 months defined by electrocardiographic (ECG) changes&#xD;
             and biomarkers of myocardial necrosis (e.g., troponin) in an appropriate clinical&#xD;
             setting (chest discomfort or anginal equivalent)&#xD;
&#xD;
          -  Percutaneous Coronary Intervention, coronary artery bypass grafting, or new&#xD;
             biventricular pacing within past 3 months&#xD;
&#xD;
          -  Obstructive hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Known infiltrative cardiomyopathy (amyloid)&#xD;
&#xD;
          -  Constrictive pericarditis or tamponade&#xD;
&#xD;
          -  Active myocarditis&#xD;
&#xD;
          -  Complex congenital heart disease&#xD;
&#xD;
          -  Active collagen vascular disease&#xD;
&#xD;
          -  More than mild aortic or mitral stenosis&#xD;
&#xD;
          -  Intrinsic (prolapse, rheumatic) valve disease with more than moderate mitral,&#xD;
             tricuspid or aortic regurgitation&#xD;
&#xD;
          -  Acute or chronic severe liver disease as evidenced by any of the following:&#xD;
             encephalopathy, variceal bleeding, International Normalized Ratio (INR) &gt; 1.7 in the&#xD;
             absence of anticoagulation treatment&#xD;
&#xD;
          -  Terminal illness (other than HF) with expected survival of less than 1 year&#xD;
&#xD;
          -  Enrollment or planned enrollment in another therapeutic clinical trial in next 3&#xD;
             months.&#xD;
&#xD;
          -  Inability to comply with planned study procedures&#xD;
&#xD;
          -  Pregnancy or breastfeeding mothers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry A Borlaug, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy G Acker, RN</last_name>
    <phone>507-266-4058</phone>
    <email>acker.nancy@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janet Gatzke, RN</last_name>
    <phone>507-538-7177</phone>
    <email>gatzke.janet@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Barry A Borlaug, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Barry Borlaug</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

